Exdensur (depemokimab-ulaa) side effects and precautions

Exdensur (depemokimab-ulaa) is a biological agent used to treat severe asthma. Although it has significant efficacy, some side effects and precautions may occur during use. Patients should be cautious when using it.

Common adverse reactions include upper respiratory tract infection, allergic rhinitis, influenza, joint pain and pharyngitis, etc. The incidence rate of these reactions is more than 4%. These side effects are usually mild, but in some cases may affect the patient's daily life. Therefore, patients should closely monitor their physical condition and communicate with their doctor in a timely manner when using Exdensur.

The most important warning when usingExdensur is the risk of allergic reactions. Some patients may experience allergic reactions after using this drug, including symptoms such as rash, itching, and difficulty breathing. In the event of an allergic reaction, discontinue use of Exdensur immediately and seek medical help for appropriate treatment.

In addition,Exdensur is not intended to treat acute asthma symptoms or exacerbations. Patients should avoid using this drug for the treatment of acute bronchospasm or status asthmaticus. If the patient's asthma symptoms cannot be controlled or the condition worsens after starting to use Exdensur, the patient should seek prompt advice from a medical professional to adjust the treatment plan.

Another caution with using Exdensurare the risks associated with corticosteroid dosage. Patients should not suddenly discontinue systemic or inhaled corticosteroids after starting Exdensur therapy. Because sudden reductions in corticosteroid doses may trigger systemic withdrawal symptoms or result in recurrence of a condition previously suppressed by corticosteroids. Therefore, when adjusting the dose of corticosteroids, it should be done gradually under the guidance of professional medical personnel to ensure safety.

In addition,The use of Exdensur also requires attention to the risk of parasitic infection. Eosinophils play an important role in the immune response to certain helminth infections. If an infection develops while receiving Exdensur and does not respond to antihelmintic treatment, use of Exdensur should be discontinued until the patient's infection is controlled.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/exdensur